Gadolinium chelate safety in pregnancy

Barely detectable gadolinium levels in the juvenile nonhuman primate after in utero exposure

Joao Prola-Netto, Mark Woods, Victoria Roberts, Elinor Sullivan, Christina Ann Miller, Antonio Frias, Karen Oh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To determine whether gadolinium remains in juvenile nonhuman primate tissue after maternal exposure to intravenous gadoteridol during pregnancy. Materials and Methods: Gravid rhesus macaques and their offspring (n = 10) were maintained, as approved by the institutional animal care and utilization committee. They were prospectively studied as part of a pre-existing ongoing research protocol to evaluate the effects of maternal malnutrition on placental and fetal development. On gestational days 85 and 135, they underwent placental magnetic resonance imaging after intravenous gadoteridol administration. Amniocentesis was performed on day 135 prior to administration of the second dose of gadoteridol. After delivery, the offspring were followed for 7 months. Tissue samples from eight different organs and from blood were harvested from each juvenile macaque. Gadolinium levels were measured by using inductively coupled plasma mass spectrometry. Results: Gadolinium concentration in the amniotic fluid was 0.028 X 10-5 %ID/g (percentage injected dose per gram of tissue) 50 days after administration of one gadoteridol dose. Gadolinium was most consistently detected in the femur (mean, 2.5 X 10-5 %ID/g; range, [0.81-4.1] X 10-5 %ID/g) and liver (mean, 0.15 X 10-5 %ID/g; range, [0-0.26] X 10-5 %ID/g). Levels were undetectable in the remaining sampled tissues, with the exception of one juvenile skin sample (0.07 X 10-5 %ID/g), one juvenile spleen sample (0.039 X 10-5 %ID/g), and one juvenile brain (0.095 X 10-5 %ID/g) and kidney (0.13 X 10-5 %ID/g) sample. Conclusion: The presence of gadoteridol in the amniotic fluid after maternal injection enables confirmation that it crosses the placenta. Extremely low levels of gadolinium are found in juvenile macaque tissues after in utero exposure to two doses of gadoteridol, indicating that a very small amount of gadolinium persists after delivery.

Original languageEnglish (US)
Pages (from-to)122-128
Number of pages7
JournalRadiology
Volume286
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Gadolinium
Primates
Safety
Pregnancy
Macaca
Amniotic Fluid
Animal Care Committees
Mothers
Maternal Exposure
Placentation
Amniocentesis
Fetal Development
Macaca mulatta
Malnutrition
Intravenous Administration
Femur
Placenta
gadoteridol
Mass Spectrometry
Spleen

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Gadolinium chelate safety in pregnancy : Barely detectable gadolinium levels in the juvenile nonhuman primate after in utero exposure. / Prola-Netto, Joao; Woods, Mark; Roberts, Victoria; Sullivan, Elinor; Miller, Christina Ann; Frias, Antonio; Oh, Karen.

In: Radiology, Vol. 286, No. 1, 01.01.2018, p. 122-128.

Research output: Contribution to journalArticle

@article{0174ce51895141918bdda6ed2f11a3b1,
title = "Gadolinium chelate safety in pregnancy: Barely detectable gadolinium levels in the juvenile nonhuman primate after in utero exposure",
abstract = "Purpose: To determine whether gadolinium remains in juvenile nonhuman primate tissue after maternal exposure to intravenous gadoteridol during pregnancy. Materials and Methods: Gravid rhesus macaques and their offspring (n = 10) were maintained, as approved by the institutional animal care and utilization committee. They were prospectively studied as part of a pre-existing ongoing research protocol to evaluate the effects of maternal malnutrition on placental and fetal development. On gestational days 85 and 135, they underwent placental magnetic resonance imaging after intravenous gadoteridol administration. Amniocentesis was performed on day 135 prior to administration of the second dose of gadoteridol. After delivery, the offspring were followed for 7 months. Tissue samples from eight different organs and from blood were harvested from each juvenile macaque. Gadolinium levels were measured by using inductively coupled plasma mass spectrometry. Results: Gadolinium concentration in the amniotic fluid was 0.028 X 10-5 {\%}ID/g (percentage injected dose per gram of tissue) 50 days after administration of one gadoteridol dose. Gadolinium was most consistently detected in the femur (mean, 2.5 X 10-5 {\%}ID/g; range, [0.81-4.1] X 10-5 {\%}ID/g) and liver (mean, 0.15 X 10-5 {\%}ID/g; range, [0-0.26] X 10-5 {\%}ID/g). Levels were undetectable in the remaining sampled tissues, with the exception of one juvenile skin sample (0.07 X 10-5 {\%}ID/g), one juvenile spleen sample (0.039 X 10-5 {\%}ID/g), and one juvenile brain (0.095 X 10-5 {\%}ID/g) and kidney (0.13 X 10-5 {\%}ID/g) sample. Conclusion: The presence of gadoteridol in the amniotic fluid after maternal injection enables confirmation that it crosses the placenta. Extremely low levels of gadolinium are found in juvenile macaque tissues after in utero exposure to two doses of gadoteridol, indicating that a very small amount of gadolinium persists after delivery.",
author = "Joao Prola-Netto and Mark Woods and Victoria Roberts and Elinor Sullivan and Miller, {Christina Ann} and Antonio Frias and Karen Oh",
year = "2018",
month = "1",
day = "1",
doi = "10.1148/radiol.2017162534",
language = "English (US)",
volume = "286",
pages = "122--128",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Gadolinium chelate safety in pregnancy

T2 - Barely detectable gadolinium levels in the juvenile nonhuman primate after in utero exposure

AU - Prola-Netto, Joao

AU - Woods, Mark

AU - Roberts, Victoria

AU - Sullivan, Elinor

AU - Miller, Christina Ann

AU - Frias, Antonio

AU - Oh, Karen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To determine whether gadolinium remains in juvenile nonhuman primate tissue after maternal exposure to intravenous gadoteridol during pregnancy. Materials and Methods: Gravid rhesus macaques and their offspring (n = 10) were maintained, as approved by the institutional animal care and utilization committee. They were prospectively studied as part of a pre-existing ongoing research protocol to evaluate the effects of maternal malnutrition on placental and fetal development. On gestational days 85 and 135, they underwent placental magnetic resonance imaging after intravenous gadoteridol administration. Amniocentesis was performed on day 135 prior to administration of the second dose of gadoteridol. After delivery, the offspring were followed for 7 months. Tissue samples from eight different organs and from blood were harvested from each juvenile macaque. Gadolinium levels were measured by using inductively coupled plasma mass spectrometry. Results: Gadolinium concentration in the amniotic fluid was 0.028 X 10-5 %ID/g (percentage injected dose per gram of tissue) 50 days after administration of one gadoteridol dose. Gadolinium was most consistently detected in the femur (mean, 2.5 X 10-5 %ID/g; range, [0.81-4.1] X 10-5 %ID/g) and liver (mean, 0.15 X 10-5 %ID/g; range, [0-0.26] X 10-5 %ID/g). Levels were undetectable in the remaining sampled tissues, with the exception of one juvenile skin sample (0.07 X 10-5 %ID/g), one juvenile spleen sample (0.039 X 10-5 %ID/g), and one juvenile brain (0.095 X 10-5 %ID/g) and kidney (0.13 X 10-5 %ID/g) sample. Conclusion: The presence of gadoteridol in the amniotic fluid after maternal injection enables confirmation that it crosses the placenta. Extremely low levels of gadolinium are found in juvenile macaque tissues after in utero exposure to two doses of gadoteridol, indicating that a very small amount of gadolinium persists after delivery.

AB - Purpose: To determine whether gadolinium remains in juvenile nonhuman primate tissue after maternal exposure to intravenous gadoteridol during pregnancy. Materials and Methods: Gravid rhesus macaques and their offspring (n = 10) were maintained, as approved by the institutional animal care and utilization committee. They were prospectively studied as part of a pre-existing ongoing research protocol to evaluate the effects of maternal malnutrition on placental and fetal development. On gestational days 85 and 135, they underwent placental magnetic resonance imaging after intravenous gadoteridol administration. Amniocentesis was performed on day 135 prior to administration of the second dose of gadoteridol. After delivery, the offspring were followed for 7 months. Tissue samples from eight different organs and from blood were harvested from each juvenile macaque. Gadolinium levels were measured by using inductively coupled plasma mass spectrometry. Results: Gadolinium concentration in the amniotic fluid was 0.028 X 10-5 %ID/g (percentage injected dose per gram of tissue) 50 days after administration of one gadoteridol dose. Gadolinium was most consistently detected in the femur (mean, 2.5 X 10-5 %ID/g; range, [0.81-4.1] X 10-5 %ID/g) and liver (mean, 0.15 X 10-5 %ID/g; range, [0-0.26] X 10-5 %ID/g). Levels were undetectable in the remaining sampled tissues, with the exception of one juvenile skin sample (0.07 X 10-5 %ID/g), one juvenile spleen sample (0.039 X 10-5 %ID/g), and one juvenile brain (0.095 X 10-5 %ID/g) and kidney (0.13 X 10-5 %ID/g) sample. Conclusion: The presence of gadoteridol in the amniotic fluid after maternal injection enables confirmation that it crosses the placenta. Extremely low levels of gadolinium are found in juvenile macaque tissues after in utero exposure to two doses of gadoteridol, indicating that a very small amount of gadolinium persists after delivery.

UR - http://www.scopus.com/inward/record.url?scp=85038921503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038921503&partnerID=8YFLogxK

U2 - 10.1148/radiol.2017162534

DO - 10.1148/radiol.2017162534

M3 - Article

VL - 286

SP - 122

EP - 128

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -